Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Innate Pharma (IPHA) DMA 50 (2017 - 2026)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|